Cecilia  Jones net worth and biography

Cecilia Jones Biography and Net Worth

Cecilia joined Agios as chief financial officer in September 2022. She has more than 20 years of financial experience within the biopharmaceutical industry, including several companies focused on rare diseases. Prior to Agios, she served as chief financial officer at LogicBio, where she was responsible for driving the company’s financial strategy, including evaluation of financing alternatives and analysis of business development opportunities, and managing corporate financial planning, accounting, corporate communications and investor relations. Before her role at LogicBio, Cecilia spent more than 10 years at Biogen in roles of increasing responsibility within the finance organization. Most recently, she was vice president of R&D, worldwide medical and business development finance, advising senior management on investment prioritization to support the company’s strategic goals. Previously, she served as senior director of corporate finance, where she led global long-range planning and financial assessment of business development and M&A opportunities, and director of finance for emerging markets, global commercial strategy and global market access. Before joining Biogen, Ms. Jones was director of international finance at Genzyme, where she held various roles of increasing responsibility within international finance. She earned a Licenciatura en Economia from Universidad de San Andres in Buenos Aires, Argentina, and an MBA from Harvard Business School.

What is Cecilia Jones' net worth?

The estimated net worth of Cecilia Jones is at least $845,829.68 as of September 26th, 2024. Ms. Jones owns 20,158 shares of Agios Pharmaceuticals stock worth more than $845,830 as of December 18th. This net worth approximation does not reflect any other assets that Ms. Jones may own. Additionally, Ms. Jones receives a salary of $403,360.00 as CFO at Agios Pharmaceuticals. Learn More about Cecilia Jones' net worth.

How old is Cecilia Jones?

Ms. Jones is currently 49 years old. There are 9 older executives and no younger executives at Agios Pharmaceuticals. The oldest executive at Agios Pharmaceuticals is Dr. Tak Wah Mak D.Sc., FRSC, Ph.D., Co-Founder & Member of Scientific Advisory Board, who is 78 years old. Learn More on Cecilia Jones' age.

What is Cecilia Jones' salary?

As the CFO of Agios Pharmaceuticals, Inc., Ms. Jones earns $403,360.00 per year. There are 3 executives that earn more than Ms. Jones. The highest earning executive at Agios Pharmaceuticals is Mr. Brian M. Goff M.B.A., CEO & Director, who commands a salary of $1,230,000.00 per year. Learn More on Cecilia Jones' salary.

How do I contact Cecilia Jones?

The corporate mailing address for Ms. Jones and other Agios Pharmaceuticals executives is 88 SIDNEY STREET, CAMBRIDGE MA, 02139. Agios Pharmaceuticals can also be reached via phone at (617) 649-8600 and via email at [email protected]. Learn More on Cecilia Jones' contact information.

Has Cecilia Jones been buying or selling shares of Agios Pharmaceuticals?

Cecilia Jones has not been actively trading shares of Agios Pharmaceuticals during the last ninety days. Most recently, Cecilia Jones sold 2,542 shares of the business's stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $49.03, for a transaction totalling $124,634.26. Following the completion of the sale, the chief financial officer now directly owns 20,158 shares of the company's stock, valued at $988,346.74. Learn More on Cecilia Jones' trading history.

Who are Agios Pharmaceuticals' active insiders?

Agios Pharmaceuticals' insider roster includes Carman Alenson (Insider), Jonathan Biller (CFO & Head of Corp. Affairs ), Christopher Bowden (Insider), James Burns (https://www.linkedin.com/in/jackie-fouse-a90b811aa), Jacqualyn Fouse (CEO & Director ), Jacqualyn Fouse (Director), Sarah Gheuens (Chief Medical Officer, Head of R&D), Brian Goff (CEO), Cecilia Jones (CFO), and Darrin Miles (Insider). Learn More on Agios Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Agios Pharmaceuticals?

In the last year, insiders at the biopharmaceutical company sold shares 17 times. They sold a total of 76,341 shares worth more than $2,120,143.90. The most recent insider tranaction occured on December, 11th when Director David Scadden sold 200 shares worth more than $9,256.00. Insiders at Agios Pharmaceuticals own 4.9% of the company. Learn More about insider trades at Agios Pharmaceuticals.

Information on this page was last updated on 12/11/2024.

Cecilia Jones Insider Trading History at Agios Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/26/2024Sell2,542$49.03$124,634.2620,158View SEC Filing Icon  
1/24/2024Sell1,886$21.64$40,813.0413,069View SEC Filing Icon  
9/28/2023Sell2,179$24.79$54,017.419,575View SEC Filing Icon  
6/30/2023Sell1,597$28.36$45,290.923,783View SEC Filing Icon  
See Full Table

Cecilia Jones Buying and Selling Activity at Agios Pharmaceuticals

This chart shows Cecilia Jones's buying and selling at Agios Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Agios Pharmaceuticals Company Overview

Agios Pharmaceuticals logo
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $42.11
Low: $40.50
High: $42.28

50 Day Range

MA: $50.09
Low: $38.17
High: $61.64

2 Week Range

Now: $42.11
Low: $20.96
High: $62.58

Volume

290,094 shs

Average Volume

719,198 shs

Market Capitalization

$2.40 billion

P/E Ratio

3.69

Dividend Yield

N/A

Beta

0.8